Camilla Guerrero
A5053570733- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Chemokine receptors and signaling
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- Peptidase Inhibition and Analysis
- SARS-CoV-2 and COVID-19 Research
- Cancer Treatment and Pharmacology
- Diet and metabolism studies
- COVID-19 Clinical Research Studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Electrolyte and hormonal disorders
- Heart Failure Treatment and Management
- Intensive Care Unit Cognitive Disorders
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- COVID-19 and healthcare impacts
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and B-cell Immunology
- Digestive system and related health
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Diverse Scientific Research Studies
Clinica Universidad de Navarra
2021-2024
Navarre Institute of Health Research
2021-2024
Centro de Investigación Biomédica en Red de Cáncer
2021-2024
Casa Colina Centers for Rehabilitation
2019
Abstract Purpose: Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor (CTC), adding immune biomarkers peripheral blood (PB) the identification of patients at progression due lost surveillance, could improve International Myeloma Working Group 20/2/20 model. Experimental Design: report outcomes 150 with SMM enrolled iMMunocell...
Abstract Purpose: Undetectable measurable residual disease (MRD) is a surrogate of prolonged survival in multiple myeloma. Thus, treatment individualization based on the probability patient achieving undetectable MRD with singular regimen could represent new concept toward personalized treatment, fast assessment its success. This has never been investigated; therefore, we sought to define machine learning model predict at onset Experimental Design: study included 487 newly diagnosed patients...
The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present a monoclonal gammopathy undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized its clinical is properly validated.An algorithm having MGUS-like was developed on the basis percentages total bone marrow (BM) plasma cells (PC) clonal PC within BM compartment, determined at diagnosis using flow cytometry in 548 MGUS 2,011...
There is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related immunosuppression can be depicted peripheral blood, immune profiling prior to vaccination help predict immunogenicity. performed a comprehensive immunological characterization 83 before measured IgM, IgG, IgA antibody response four viral antigens at day +7 after second-dose COVID-19 using multidimensional computational flow cytometry....
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. In myeloma (MM), measurable residual disease (MRD) is assessed bone marrow (BM). However, less invasive evaluation...
Background: Central pontine myelinolysis is a rare condition that can result in debilitating symptoms. Recent evidence suggests shift hypothesized prognosis for individuals with this diagnosis and implies valuable role rehabilitation to address prevention of secondary complications functional recovery. This paper describes 30 year-old female central presenting incomplete locked-in syndrome chronicles her rehabilitative journey at comprehensive post-acute center. We present discipline...
Abstract Infection is the leading cause of death in multiple myeloma (MM). However, cellular composition associated with immune dysfunction not defined. We analyzed profiles peripheral blood patients MM ( n = 28) and B-cell chronic lymphoproliferative disorders 53) vs. health care practitioners 96), using multidimensional computational flow cytometry. displayed altered distribution most cell types (41/56, 73%), particularly within (17/17) T-cell (20/30) compartments. Using COVID-19 as a case...
<div>AbstractPurpose:<p>Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor (CTC), adding immune biomarkers peripheral blood (PB) the identification of patients at progression due lost surveillance, could improve International Myeloma Working Group 20/2/20 model.</p>Experimental Design:<p>We report outcomes...
<div>AbstractPurpose:<p>Undetectable measurable residual disease (MRD) is a surrogate of prolonged survival in multiple myeloma. Thus, treatment individualization based on the probability patient achieving undetectable MRD with singular regimen could represent new concept toward personalized treatment, fast assessment its success. This has never been investigated; therefore, we sought to define machine learning model predict at onset myeloma.</p>Experimental...
Supplementary Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma